ストックスクリーナーアプリを入手
14.30
3.25%
-0.48
前日終値:
$14.78
開ける：
$14.8
24時間の取引高:
966.69K
Relative Volume:
0.70
時価総額：
$1.22B
収益：
$42.95M
当期純損益:
$-130.01M
株価収益率:
-8.7849
EPS:
-1.6278
ネットキャッシュフロー:
$-19.66M
1週間 パフォーマンス:
-7.74%
1か月 パフォーマンス:
-39.48%
6か月 パフォーマンス:
-24.66%
1年 パフォーマンス:
+217.78%
1日の値動き範囲:
$14.17
$15.00
1週間の範囲:
$14.17
$16.20
52週間の値動き範囲:
$4.515
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
名前
Monte Rosa Therapeutics Inc
セクター
電話
617-949-2643
住所
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
14.30 | 1.26B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 開始されました | UBS | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
すべてを表示
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
GLUE|Monte Rosa Therapeutics Inc|Price:15.500|Chg%:-0.340 - TradingKey
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - marketbeat.com
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Monte Rosa Therapeutics (GLUE) Climbs 1.08% as Shares Hold Above Key Support at $15.09Time Weighted Price - vinanet.vn
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - marketbeat.com
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D - TradingView
Monte Rosa posts $43.4 million Q2 loss as pipeline trials advance - Quiver Quantitative
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M - Moomoo
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029 - TradingView
Monte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView
Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop - Stock Titan
BRIEF-Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million - TradingView
Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Moomoo
Monte Rosa Q2 2026 earnings: Higher R&D widens loss as pipeline advances - TradingKey
Monte Rosa earnings on deck as cardiovascular data looms By Investing.com - Investing.com India
Monte Rosa Eyes Key Pipeline Readouts; Wedbush Analyst Reiterates Outperform Rating - RTTNews
Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush - MarketBeat
Monte Rosa Therapeutics (GLUE) Plunges 27%: Critical Support Test After Steep SelloffConversion Trade - dars.gov.et
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Why is Monte Rosa Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline - Seeking Alpha
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics Inc - TradingKey
Monte Rosa Therapeutics Inc (GLUE) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):